BACKGROUND: Plasma thymus and activation-regulated chemokine is a potential biomarker for classical Hodgkin's lymphoma. To define its value as a marker to monitor treatment response, we correlated serial plasma thymus and activation-regulated chemokine levels with clinical response in newly diagnosed and relapsed classical Hodgkin's lymphoma patients. DESIGN AND METHODS: Plasma was collected from 60 (39 early stage and 21 advanced stage) newly diagnosed classical Hodgkin's lymphoma patients before, during, and after treatment, and from 12 relapsed patients before and after treatment. Plasma thymus and activation-regulated chemokine levels were determined by enzyme-linked immunosorbent assay and were related to pre-treatment metabolic tumor volume, as measured by quantification of 2-[18F]fluoro-2-deoxyglucose positron emission tomography images, and to treatment response. RESULTS: Baseline plasma thymus and activation-regulated chemokine levels correlated with stage of disease and bulky disease, and more closely with metabolic tumor volume. Response to treatment was observed among 38 of 39 early stage and 19 of 21 advanced stage patients. Reduction in plasma thymus and activation-regulated chemokine to normal range levels could be observed as early as after one cycle of chemotherapy in all responsive patients, while plasma levels remained elevated during and after treatment in the 3 non-responsive patients. Plasma thymus and activation-regulated chemokine was elevated in all 12 relapsed patients at time of relapse and remained elevated after salvage treatment in the 4 non-responsive patients. CONCLUSIONS: Baseline plasma thymus and activation-regulated chemokine levels correlate with classical Hodgkin's lymphoma tumor burden and serial levels correlate with response to treatment in patients with classical Hodgkin's lymphoma.
BACKGROUND: Plasma thymus and activation-regulated chemokine is a potential biomarker for classical Hodgkin's lymphoma. To define its value as a marker to monitor treatment response, we correlated serial plasma thymus and activation-regulated chemokine levels with clinical response in newly diagnosed and relapsed classical Hodgkin's lymphomapatients. DESIGN AND METHODS: Plasma was collected from 60 (39 early stage and 21 advanced stage) newly diagnosed classical Hodgkin's lymphomapatients before, during, and after treatment, and from 12 relapsed patients before and after treatment. Plasma thymus and activation-regulated chemokine levels were determined by enzyme-linked immunosorbent assay and were related to pre-treatment metabolic tumor volume, as measured by quantification of 2-[18F]fluoro-2-deoxyglucose positron emission tomography images, and to treatment response. RESULTS: Baseline plasma thymus and activation-regulated chemokine levels correlated with stage of disease and bulky disease, and more closely with metabolic tumor volume. Response to treatment was observed among 38 of 39 early stage and 19 of 21 advanced stage patients. Reduction in plasma thymus and activation-regulated chemokine to normal range levels could be observed as early as after one cycle of chemotherapy in all responsive patients, while plasma levels remained elevated during and after treatment in the 3 non-responsive patients. Plasma thymus and activation-regulated chemokine was elevated in all 12 relapsed patients at time of relapse and remained elevated after salvage treatment in the 4 non-responsive patients. CONCLUSIONS: Baseline plasma thymus and activation-regulated chemokine levels correlate with classical Hodgkin's lymphoma tumor burden and serial levels correlate with response to treatment in patients with classical Hodgkin's lymphoma.
Authors: Martin R Weihrauch; Oliver Manzke; Marc Beyer; Heinz Haverkamp; Volker Diehl; Heribert Bohlen; Juergen Wolf; Joachim L Schultze Journal: Cancer Res Date: 2005-07-01 Impact factor: 12.701
Authors: Hervé Ghesquières; Matthew J Maurer; Olivier Casasnovas; Stephen M Ansell; Beth R Larrabee; Eva Lech-Maranda; Anne J Novak; Anne-Laure Borrel; Susan L Slager; Pauline Brice; Cristine Allmer; Annie Brion; Steven C Ziesmer; Franck Morschhauser; Thomas M Habermann; Isabelle Gaillard; Brian K Link; Aspasia Stamatoullas; Christophe Fermé; Ahmet Dogan; William R Macon; Josée Audouin; James R Cerhan; Gilles Salles Journal: Cytokine Date: 2013-09-03 Impact factor: 3.861
Authors: Nathan H Fowler; Chan Yoon Cheah; Randy D Gascoyne; John Gribben; Sattva S Neelapu; Paolo Ghia; Catherine Bollard; Stephen Ansell; Michael Curran; Wyndham H Wilson; Susan O'Brien; Cliona Grant; Richard Little; Thorsten Zenz; Loretta J Nastoupil; Kieron Dunleavy Journal: Haematologica Date: 2016-05 Impact factor: 9.941
Authors: Peter D Cole; Kathleen M McCarten; Qinglin Pei; Menachem Spira; Monika L Metzger; Richard A Drachtman; Terzah M Horton; Rizvan Bush; Susan M Blaney; Brenda J Weigel; Kara M Kelly Journal: Lancet Oncol Date: 2018-08-16 Impact factor: 41.316
Authors: Julia Driessen; Marie José Kersten; Lydia Visser; Anke van den Berg; Sanne H Tonino; Josée M Zijlstra; Pieternella J Lugtenburg; Franck Morschhauser; Martin Hutchings; Sandy Amorim; Thomas Gastinne; Marcel Nijland; Gerben J C Zwezerijnen; Ronald Boellaard; Henrica C W de Vet; Anne I J Arens; Roelf Valkema; Roberto D K Liu; Esther E E Drees; Daphne de Jong; Wouter J Plattel; Arjan Diepstra Journal: Leukemia Date: 2022-10-14 Impact factor: 12.883
Authors: Alessandra Romano; Calogero Vetro; Giovanni Caocci; Marianna Greco; Nunziatina Laura Parrinello; Francesco Di Raimondo; Giorgio La Nasa Journal: Mediterr J Hematol Infect Dis Date: 2014-06-01 Impact factor: 2.576
Authors: Annarosa Cuccaro; Salvatore Annunziata; Elisa Cupelli; Maurizio Martini; Maria L Calcagni; Vittoria Rufini; Manuela Giachelia; Francesca Bartolomei; Eugenio Galli; Francesco D'Alò; Maria T Voso; Giuseppe Leone; Alessandro Giordano; Luigi M Larocca; Stefan Hohaus Journal: Cancer Med Date: 2016-01-13 Impact factor: 4.452